-
<![CDATA[FDA Grants Full Approval to Tarlatamab in Small Cell Lung Cancer]]>
20 Nov 2025 10:47 GMT
… with extensive stage small cell lung cancer (ES-SCLC) with … aggressive nature, small cell lung cancer has long been particularly … ), topotecan (n = 185), or amrubicin (n = 23).
The primary end … for extensive-stage small-cell lung cancer. FDA. November 19, 2025 …
-
<![CDATA[FDA Approves Tarlatamab-Dlle to Treat Adults With Extensive Stage Small Cell Lung Cancer]]>
20 Nov 2025 05:20 GMT
… Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)
ClinicalTrials.gov … chemotherapy—either topotecan, lurbinectedin, or amrubicin—(n = 255) until disease … Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …
-
<![CDATA[FDA Grants Full Approval to Tarlatamab for Extensive-Stage Small Cell Lung Cancer]]>
20 Nov 2025 04:24 GMT
… topotecan (n = 185), or amrubicin (n = 23). They were … chemotherapy (topotecan/amrubicin vs lurbinectedin).
The trial … extensive stage small cell lung cancer. FDA. November 19, … Tarlatamab in small-cell lung cancer after platinum-based chemotherapy …
-
<![CDATA[FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer]]>
19 Nov 2025 22:07 GMT
… with extensive-stage small cell lung cancer (ES-SCLC) with disease … patients with small cell lung cancer whose disease had grown … be topotecan, lurbinectedin or amrubicin. Patients stayed on treatment … For Some With Small Cell Lung Cancer.” CURE; Oct. 18, …
-
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
19 Nov 2025 20:04 GMT
… with extensive stage small cell lung cancer (ES-SCLC) with disease progression … (SOC) chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression or unacceptable …
-
<![CDATA[DLL3 Emerges as an Actionable Target in Small Cell Lung Cancer]]>
27 Sep 2025 13:14 GMT
… topotecan (n = 185), or amrubicin (n = 23).
The primary … previously treated small cell lung cancer receiving tarlatamab: results … treatment for small cell lung cancer (SCLC): primary analysis … Tarlatamab in small-cell lung cancer after platinum-based …
-
Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer
08 Sep 2025 00:53 GMT
… of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1 … (Zepzelca; 21.2%), amrubicin (8.8%), DLL3-targeting … of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … with relapsed small cell lung cancer (IDeate-Lung02). Clinical …
-
Greek Researchers Lead Breakthrough Lung Cancer Study
02 Aug 2025 00:20 GMT
… drugs, including topotecan, lurbinectedin, or amrubicin. Results from the interim analysis … planned for World Lung Cancer Day
Coinciding with World Lung Cancer Day on Aug … of immunotherapy in small-cell lung cancer healthcare.
Greek contribution draws …
-
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
21 Jun 2025 02:01 GMT
… transforming the treatment landscape for lung cancer, offering new hope for patients … with both small cell lung cancer (SCLC) and non-SCLC (NSCLC … ; Jazz), topotecan (Hycamtin; Sandoz), and amrubicin (Calsed; Nippon Kayaku). The results …
-
Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer
10 Jun 2025 16:07 GMT
… with relapsed small-cell lung cancer (SCLC) compared to … patients with small-cell lung cancer (SCLC) whose disease … topotecan, lurbinectedin, or amrubicin, while producing improvements in … in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …